(c) 2024 PillSync.com

Cestex (epsiprantel 12.5 mg) Dailymed

  1. Prescription Animal
  2. Archived
  3. Pfizer Animal Health

Generic: epsiprantel

Cestex tablet, film coated - (epsiprantel 12.5 mg) image

IMPRINT: 220     SHAPE: round
    COLOR: brown    SCORE: 2

  1. FDA Adverse Reactions

Go PRO for all pill images

Caution


Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cestex (epsiprantel) tablets are indicated for the removal of tapeworms in the cat (Dipylidium caninum and Taenia taeniaeformis) and dog (Dipylidium caninum and Taenia pisiformis).

Description


Cestex tablets are film-coated and contain 12.5 mg, 25 mg, 50 mg or 100 mg of epsiprantel per tablet.

Epsiprantel is an anthelmintic that is active as a single dose against the common tapeworms of cats and dogs. Epsiprantel has a molecular weight of 326 and is chemically 2-(cyclohexyl-carbonyl)-4-oxo 1,2,3,4,6,7,8,12b-octahydropyrazino[2,1-a][2]benza-zepine. It is a stable white solid which is sparingly soluble in water. Its chemical structure is presented below.

Action


Epsiprantel acts directly on the tapeworm. Since it is minimally absorbed following oral administration, epsiprantel remains at the site of action within the gastrointestinal tract. Due to digestive process, tapeworm fragments or proglottids may not be readily visible in the stool.

Indications


Cestex tablets are indicated for the removal of the following:

Feline cestodes: Dipylidium caninum and Taenia taeniaeformis Canine cestodes: Dipylidium caninum and Taenia pisiformis

Dosage And Administration


Cestex tablets should be administered orally.

The recommended dosage of epsiprantel is: cats, 1.25 mg/lb of body weight; dogs, 2.5 mg/lb of body weight. The following table may be used as a guide:
Dosage Schedule
Feline
Body Weight Dose
Seven weeks old up to 10 lb 12.5 mg
11–20 lb 25.0 mg
Canine
Body Weight Dose
Seven weeks old up to 5 lb 12.5 mg
6–10 lb 25.0 mg
11–20 lb 50.0 mg
21–40 lb 100.0 mg
41–50 lb 125.0 mg
51–60 lb 150.0 mg
61–80 lb 200.0 mg
81–90 lb 225.0 mg
91–100 lb 250.0 mg
101+ lb 2.5 mg/lb, rounding up to next whole tablet combination

Fasting is not necessary or recommended.

Unless exposure to the infected intermediate hosts is controlled, reinfection is likely and retreatment may be required. In the case of D. caninum, an effective flea control program should be instituted.

Safety


Epsiprantel has been evaluated in cats at 5 times the recommended dose given once daily for 3 days with no adverse effects noted. In tolerance studies, epsiprantel produced minimal clinical signs in cats given 40 times the recommended dose once daily for 4 days.

Epsiprantel has been evaluated in 14-day repeat dose studies in dogs at 500 mg/kg (90 times recommended dosage) with no significant adverse results. No side effects were observed during the clinical field studies.

Epsiprantel is not a cholinesterase inhibitor. During the course of clinical field studies, Cestex was administered concurrently with diethylcarbamazine citrate (dogs only), anti-inflammatory agents, insecticides, and nematocides with no drug incompatibilities noted.

Contraindications


There are no known contraindications to the use of this drug.

Warnings


For use in cats and dogs only. Safety of use in pregnant or breeding animals has not been determined. Keep out of reach of children. Not for use in humans.

Precaution


Do not use in kittens or puppies less than 7 weeks of age.

Storage


Store at controlled room temperature 15°–30°C (59°–86°F).

How Supplied


Cestex tablets are film-coated and contain 12.5 mg, 25 mg, 50 mg or 100 mg of epsiprantel per tablet. Cestex is supplied as described below:
Weight (lbs) Number Tablets/Bottle
Concentration Cat Dog
12.5 mg 10 5 50, 100
25.0 mg 20 10 50, 100
50.0 mg – – 20 25, 50
100.0 mg – – 40 25, 50


NADA #140-893, Approved by FDA



75-8032-10January 2004

Principal Display Panel - 50 12.5 Mg Tablet Bottle Label


Cestex ® (epsiprantel)

Caution: Federal law restricts thisdrug to use by or on the order ofa licensed veterinarian.

12.5 mg

50 tablets

NADA #140-893, Approved by FDA

Pfizer

Principal Display Panel - 100 12.5 Tablet Bottle Label


Cestex ® (epsiprantel)

Caution: Federal law restricts thisdrug to use by or on the order ofa licensed veterinarian.

12.5 mg

100 tablets

NADA #140-893, Approved by FDA

Pfizer

Principal Display Panel - 50 25 Mg Tablet Bottle Label


Cestex ® (epsiprantel)

Caution: Federal law restricts thisdrug to use by or on the order ofa licensed veterinarian.

25 mg

50 tablets

NADA #140-893, Approved by FDA

Pfizer

Principal Display Panel - 100 25 Mg Tablet Bottle Label


Cestex ® (epsiprantel)

Caution: Federal law restricts thisdrug to use by or on the order ofa licensed veterinarian.

25 mg

100 tablets

NADA #140-893, Approved by FDA

Pfizer

Principal Display Panel - 25 50 Mg Tablet Bottle Label


Cestex ® (epsiprantel)

Caution: Federal law restricts thisdrug to use by or on the order ofa licensed veterinarian.

50 mg

25 tablets

NADA #140-893, Approved by FDA

Pfizer

Principal Display Panel - 50 50 Mg Tablet Bottle Label


Cestex ® (epsiprantel)

Caution: Federal law restricts thisdrug to use by or on the order ofa licensed veterinarian.

50 mg

50 tablets

NADA #140-893, Approved by FDA

Pfizer

Principal Display Panel - 25 100 Mg Tablet Bottle Label


Cestex ® (epsiprantel)

Caution: Federal law restricts thisdrug to use by or on the order ofa licensed veterinarian.

100 mg

25 tablets

NADA #140-893, Approved by FDA

Pfizer

Principal Display Panel - 50 100 Mg Tablet Bottle Label


Cestex ® (epsiprantel)

Caution: Federal law restricts thisdrug to use by or on the order ofa licensed veterinarian.

100 mg

50 tablets

NADA #140-893, Approved by FDA

Pfizer

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site